Posted on

Wellbeing Digital Sciences Provides Commercial and Corporate Updates for KGK Science

Wellbeing Digital Sciences Provides Commercial and Corporate Updates for KGK Science

The Company’s Wholly Owned Contract Research Organization has Recently Signed a Number of New Contracts, Completed Clinical Research Reports and Obtained Regulatory Approvals, Among Other Achievements by its Staff

‍Vancouver, British Columbia, April 19, 2022 / Globe Newswire / – Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics, as supported by clinical research is pleased to provide a commercial and corporate update regarding the recent achievements of its wholly owned subsidiary, KGK Science Inc., (“KGK” or the “CRO”). The first quarter of 2022 has delivered significant opportunities for KGK as new contracts have been signed, clinical research reports have been completed, regulatory approvals have been obtained and other honours have been bestowed upon the CRO. 

During the first quarter of 2022, KGK’s research team finalized two clinical study reports – a COVID-19 virtual study and an immune function study. Its regulatory team was able to complete gap analysis for a propriety delivery system in March and obtained regulatory approvals for two clinical trials that include a mood and an immune health clinical trial. The CRO’s regulatory team also conducted claims reviews for two dietary supplement companies and one food company, as well as a label review for a dietary supplement. Regarding new business, KGK signed six contracts over the last month including an Ames study, three claims reviews, two path-to-market and gap analysis engagements, two product licence applications, a consulting project for claims regarding a supplement and a manuscript. 

Dr. Mal Evans, Chief Scientific Officer of KGK, will be serving as a judge for the 2022 Nutraingredients Awards (the “Awards”), which will be her second year as a judge for these prestigious awards. The Awards honour the best and brightest ingredients, products, companies, people and initiatives in the nutrition and dietary supplements industry. This is the eighth year that the Awards will be held, with the winners being announced during a presentation ceremony on May 4, 2022. More information on the 2022 Nutraingredient Awards can be found on its website: https://nutraingredients-awards.com/live/en/page/home

Andrew Charrette, Director of Regulatory Affairs and Psychedelic Advisor at KGK, has been invited to be a panellist at Lift&Co. Expo (the “Expo”) in Toronto, Canada. He will guide a session on New Psychedelics Data: The Latest Industry Analysis for Canadian Psychedelics. The Expo will take place from May 12- 15, 2022 at the Metro Toronto Convention Centre in Toronto, Canada. The Expo is known for being the number one cannabis conference and trade show in Canada.More information on the Lift&Co. Expo can be found on its Twitter page: https://twitter.com/liftandco

KGK has also been invited to present virtually at Nutrition 2022 Live Online (“Nutrition 2022”), the American Society for Nutrition’s annual flagship meeting, on June 14 – 16, 2022. Nutrition 2022 is an event that addresses scientific and clinical topics while offering scientific presentations, live Q&A, small group discussions and networking opportunities The meeting will allow KGK the opportunity to showcase its successful findings of a clinical trial that examined the use of natural health products to support immunity during flu season. KGK submitted an abstract that it authored, for “A Randomized, Triple-Blind, Placebo-Controlled Clinical Trial Investigating Two Dietary Supplements on Supporting Immune Function in Healthy Adults in a Flu Vaccine Model”. More information about Nutrition 2022 can be found on its website: https://nutrition.org/nutrition-2022-live-online/

Management Commentary

“The team at KGK has been busy to start 2022 and I would like to commend them on their successes this year to date. I am grateful for all the hard work that has been expended by my colleagues and staff in order to have the privilege of providing this strong update. Also, I am proud of Dr. Mal Evans and Mr. Andrew Charrette for being asked to represent KGK at the 2022 Nutraingredients Awards and the Lift&Co. Expo, respectively,” said Najla Guthrie, CEO of Wellbeing. “KGK, as a core component of Wellbeing and its comprehensive strategy to re-conceptualize mental health care service offerings to patients, continues to strengthen as a business. We are confident in our plan to foster innovation in mental health services through contract research support, innovative solutions and digital therapeutics backed by scientific evidence, for Wellbeing’s expanding North American footprint and clinical expert network,” added Ms. Guthrie.

ABOUT KGK SCIENCE

Founded in 1997, KGK is a leading North American contract research organization based in London, Ontario that primarily provides high-quality clinical research trials with a focus on nutraceutical and emerging health care products. The business has successfully helped hundreds of companies with custom-designed clinical trials and claim substantiation strategies to move products into global markets. KGK’s other existing service lines include expert regulatory support and compliance solutions, participant recruitment, research support services and consulting services. On an approximate basis, the business to date has produced 150 publications, executed over 400 clinical trials across more than 40 indications, amassed 25,000 participants in its database and collected 10 million data points.

‍

ABOUT WELLBEING DIGITAL SCIENCES

Wellbeing Digital Sciences Inc. is an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics, as supported by clinical research. Its mission is supported by a network of North American clinics that provide forward-thinking therapies and other types of treatment to patients as well as through a contract research organization that offers clinical trials services to clients pursuing drug development. In essence, the Company exists to make breakthrough treatments more accessible and to offer patients transformational experiences.

On behalf of:

WELLBEING DIGITAL SCIENCES INC.

“Najla Guthrie“

Najla Guthrie, CEO

For further information, please contact:

Nick Kuzyk, Investor Relations

Tel: 1-844-746-6351

Email: ir@wellbeingdigital.co 

Web: www.wellbeingdigital.co

Twitter: @Wellbeing_IR

Notice Regarding Forward-Looking Information:

This news release contains forward-looking statements including but not limited to statements regarding the Company’s business, assets or investments, as well other statements that are not historical facts. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. These assumptions, risks and uncertainties include, among other things, the state of the economy in general and capital markets in particular, investor interest in the business and prospects of the Company.

The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities law. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made, by third parties in respect of the matters discussed above.

Endnotes

  1. “The 2022 Nutraingredients Awards”, NUTRAingredients, 2022, https://nutraingredients-awards.com/live/en/page/home
  2. “Lift & Co. Expo 2022 Toronto”, CBS trade shows global, 2022,  https://www.cantonfair.net/event/11780-lift-co-expo
  3. “Non-Stop Learning and Engagement”, American Society for Nutrition, 2022, https://nutrition.org/nutrition-2022-live-online/
Posted on

Wellbeing Digital Sciences’ New CEO Unveils Evolved Competitive Strategy

Wellbeing Digital Sciences’ New CEO Unveils Evolved Competitive Strategy

The Company’s Mission is Now to Enrich Lives Through Enhanced Mental Health Services via its Core Pillars of Contract Research, Treatment Clinics and Digital Therapeutics

VANCOUVER, British Columbia, April 14, 2022 (GLOBE NEWSWIRE) — Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics, supported by clinical research, is pleased to announce the start of a global and comprehensive strategy, mission and vision for Wellbeing by its recently appointed Chief Executive Officer (“CEO”), Najla Guthrie. The plan involves expanding the Company’s primary focus and re-engineering of psychedelic treatment services offered throughout North America. Wellbeing will work to establish next-generation mental health clinics, contemporize existing clinic facilities and launch best-in-class adjunct programs to improve patient treatment outcomes. With expertise spanning several areas of mental health treatments as well as contract research, Wellbeing will facilitate the development and clinical adoption of novel mental health treatments. The comprehensive plan is expected to bolster Wellbeing’s goal of becoming the healthcare model of choice in North America for the treatment of mental illnesses.

The Company’s pursuits are to be centred around the following values and mission:

  • To enrich lives through mental healthcare services;
  • To transform lives, improve patient experience, through a contemporary, global and comprehensive mental healthcare model of service;
  • To equip clinicians with new tools to complement existing pharmacotherapeutic approaches;
  • To re-conceptualize the way mental health services are delivered to the community; and
  • To make a positive impact on the lives of patients, create an active network of collaborating mental heath experts, foster future innovation, and re-engineer the way present-day mental healthcare services are delivered to create change and improve patient outcomes.

By the age of 40, approximately 50% of the population will suffer or have suffered from a mental health illness.1 Accordingly, the Company’s management team deems it to be more important now than ever to find innovative and effective solutions to address mental illness issues. Wellbeing aims to conduct contract research and provide novel technology-enabled solutions backed by scientific evidence, to clinics around North America, by using digital therapeutics to complement physical therapy, psychotherapy, pain management and psychedelic-based treatments. The Company also intends to create a contemporary network of collaborating clinicians to bring forth the best mental health services under its re-conceptualized plan.

“The evidence shows that patient access to mental healthcare remains one of the primary issues of the mental health crisis. Both the psychedelic medicine and digital therapeutics sectors are moving at lightspeed to address this, but they face two major obstacles; clinical development to gain regulatory approvals, and clinical adoption by the medical establishment. Wellbeing provides a solution to both of these problems faced by industry which more importantly allows us to provide our patients with early access to life-saving treatments,” said Najla Guthrie, CEO of Wellbeing.

“We are passionate about being part of the evolution to foster initial change in the current mental health system and re-evaluate future change through our Wellbeing expert network. By incorporating these changes to differentiate our ability to improve mental health outcomes, we look forward to demonstrating the positive impact we are creating in patients through clinical research. As the driver of innovative change in how mental health care is delivered in the future, we create value for our patients, clinician network, shareholders, and stakeholders,” added Ms. Guthrie.

ABOUT WELLBEING DIGITAL SCIENCES

Wellbeing Digital Sciences Inc. is an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics, supported by clinical research. Its mission is supported by a network of North American clinics that provide innovative mental health treatments, digital therapeutic treatments and proprietary physical therapy, among others, as well as a contract research organization that offers clinical trials services to clients pursuing drug or device development. In essence, the Company exists to make breakthrough treatments more accessible and to offer patients transformational experiences.

On behalf of:

WELLBEING DIGITAL SCIENCES INC.

“Najla Guthrie”
Najla Guthrie, CEO

For further information, please contact:

Nick Kuzyk, Investor Relations
Tel: 1-844-746-6351
Email: ir@wellbeingdigital.co
Web: www.wellbeingdigital.co
Twitter: @Wellbeing_IR

Notice Regarding Forward-Looking Information:

This news release contains forward-looking statements including but not limited to statements regarding the Company’s business, assets or investments, as well other statements that are not historical facts. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. These assumptions, risks and uncertainties include, among other things, the state of the economy in general and capital markets in particular, investor interest in the business and prospects of the Company.

The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities law. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made, by third parties in respect of the matters discussed above.

Posted on

Wellbeing Digital Sciences Welcomes Najla Guthrie as Chief Executive Officer

Wellbeing Digital Sciences Welcomes Najla Guthrie as Chief Executive Officer

The Company is Well Positioned to Leverage the Recent Success Announced by  its KGK Science and IRP Health Subsidiaries Under Ms. Guthrie’s Leadership  

Vancouver, British Columbia, April 4, 2022 / Globe Newswire / – Wellbeing Digital Sciences Inc.  (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based  healthcare company focused on innovative clinical solutions, artificial intelligence-powered digital  therapeutics and contract research, and its Board of Directors are pleased to welcome Najla Guthrie as its  new Chief Executive Officer (“CEO”) effective March 31, 2022. Ms. Guthrie has been appointed to lead  the development of an evolved competitive strategy through a refreshed mission and vision for the  Company. The previously announced accomplishments by Wellbeing’s wholly owned subsidiaries, KGK  Science Inc. (“KGK”) and IRP Health (“IRP”), have positioned it well for Ms. Guthrie’s tenure as  Wellbeing’s new leader.  

Ms. Guthrie has been the President and CEO of KGK since 1997 and most recently also held the title of  Chief Science Officer for Wellbeing. Over the years, Najla has grown KGK into a leading North American  contract research organization that provides high-quality clinical research trials with a focus on the  nutraceutical, cannabis, and emerging psychedelic industries. Ms. Guthrie has been instrumental in  publishing over 50 papers in peer-reviewed journals and has given numerous presentations at both the  national and international levels. Najla is aptly fitted for her new role as CEO of Wellbeing and is highly  regarded in the research, science, and leadership communities.  

As a summary of the Company’s recent achievements, KGK was selected by Lophos Pharmaceuticals Inc.  for a novel study to evaluate a path to market for sustainably grown peyote-derived natural health products.  Wellbeing has also commenced its single arm, open label study of patients with post-traumatic stress  disorder who are undergoing the proprietary physical therapy program at IRP clinics. IRP has also recently  had its innovative Reactivation therapy program formally approved by Veterans Affairs Canada as an  interdisciplinary clinic outpatient program at three locations, which sets Wellbeing up for continued success  on the path to expanding its treatment of veterans and first responders across Canada. Lastly, the inpatient  Ketamine Integrated Therapy Experience program in association with Victoria Wellness continues to  successfully improve the quality of life for patients through IV ketamine treatments.  

Regarding the Company’s intent to obtain a listing through an initial public offering on a more senior stock  exchange in the United States, it has completed its GAAP-based audit for fiscal 2020 and is now finalizing  the fiscal 2021 audit. Wellbeing has also made significant progress on completing the necessary filing 

requirements and it continues to work with its advisors on achieving this important capital markets  initiative.  

Management Commentary  

“It is an honour to be welcomed as the new CEO of Wellbeing. I am grateful to Adam Deffett and his hard  work as Interim CEO and his positive contributions to Wellbeing since last year. I am ready to lead the  Company, am optimistic for its future and feel that we can truly make a difference in the mental health  industry to help alleviate the crisis that we are facing,” said Najla Guthrie, CEO of Wellbeing. “I am proud  of the accomplishments that both KGK and IRP have announced over the last few months. They reaffirm  the value of both businesses as part of Wellbeing’s greater whole, along with our joint emphasis on digital  therapeutics as our third strategic pillar. I look forward to making a positive and lasting impact on the way  that mental health illnesses are viewed and treated,” added Ms. Guthrie.  

ABOUT KGK SCIENCE 

Founded in 1997, KGK is a leading North American contract research organization based in London,  Ontario that primarily provides high-quality clinical research trials with a focus on the nutraceutical and  emerging health care products. The business has successfully helped hundreds of companies with custom  designed clinical trials and claim substantiation strategies to move products into global markets. KGK’s  other existing service lines include expert regulatory support and compliance solutions, participant  recruitment, research support services and consulting services. On an approximate basis, the business to  date has produced 150 publications, executed over 400 clinical trials across more than 40 indications,  amassed 25,000 participants in its database and collected 10 million data points.  

ABOUT WELLBEING DIGITAL SCIENCES 

Wellbeing Digital Sciences Inc. is an evidence-based healthcare company focused on innovative clinical  solutions, artificial intelligence-powered digital therapeutics and contract research. Its mission is supported  by a network of North American clinics that provide ketamine-assisted therapies and other types of  treatment to patients as well as through a contract research organization that offers clinical trials services  to clients pursuing drug development. In essence, the company exists to make breakthrough treatments  more accessible and to offer patients transformational experiences.  

On behalf of:  

WELLBEING DIGITAL SCIENCES INC. 

“Najla Guthrie”  

Najla Guthrie, CEO  

For further information, please contact:  

Nick Kuzyk, Investor Relations  

Tel: 1-844-746-6351  

Email: ir@wellbeingdigital.co  

Web: www.wellbeingdigital.co 

Twitter: @Wellbeing_IR  

Notice Regarding Forward-Looking Information:

This news release contains forward-looking statements including but not limited to statements regarding  the Company’s business, assets or investments, as well other statements that are not historical facts. Readers  are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that  the plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking  statements involve numerous assumptions, known and unknown risks and uncertainties, both general and  specific, that contribute to the possibility that the predictions, forecasts, projections and other forward 

looking statements will not occur, which may cause actual performance and results in future periods to  differ materially from any estimates or projections of future performance or results expressed or implied by  such forward-looking statements. These assumptions, risks and uncertainties include, among other things,  the state of the economy in general and capital markets in particular, investor interest in the business and  prospects of the Company.  

The forward-looking statements contained in this news release are made as of the date of this news release.  Except as required by law, the Company disclaims any intention and assumes no obligation to update or  revise any forward-looking statements, whether as a result of new information, future events or otherwise,  except as required by applicable securities law. Additionally, the Company undertakes no obligation to  comment on the expectations of, or statements made, by third parties in respect of the matters discussed  above.  

‍

Posted on

Wellbeing Digital Sciences Announces Restructuring of Security-Based Compensation

Wellbeing Digital Sciences Announces Restructuring of Security-Based Compensation

Vancouver, British Columbia, March 28, 2022 / Globe Newswire / – Wellbeing Digital Sciences Inc.  (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based  healthcare company focused on innovative clinical solutions, artificial intelligence-powered digital  therapeutics and contract research, today announced that it has granted 5,099,999 compensation stock  options (the “Options”) and 3,000,000 restricted share units (the “RSUs”) to certain directors, officers,  employees, advisors, and consultants of the Company. The Options shall vest immediately and be  exercisable into common shares at a price of $0.215 per Option for a period of 5 years from issuance. The  RSUs are subject to future vesting with one quarter vesting at each of 3, 6, 9, and 12 months from the date  of issuance and shall be exercisable for 24 months. The Options and RSUs are issued as part of its  compensation programs to incentivize and retain its board of directors, executives, and managers.  

Additionally, the Company announced that it has cancelled 2,975,000 incentive stock options (the  “Cancelled Options”) and 5,000,000 RSUs pursuant to the terms of its stock option plan and restricted  share unit plan, respectively. The Cancelled Options had been granted between March 22, 2021 and July 5,  2021 to several consultants of the Company and were voluntarily surrendered by the holders for no  consideration.  

ABOUT WELLBEING DIGITAL SCIENCES 

Wellbeing Digital Sciences Inc. is an evidence-based healthcare company focused on innovative clinical  solutions, artificial intelligence-powered digital therapeutics and contract research. Its mission is supported  by a network of North American clinics that provide ketamine-assisted therapies and other types of  treatment to patients as well as through a contract research organization that offers clinical trials services  to clients pursuing drug development. In essence, the company exists to make breakthrough treatments  more accessible and to offer patients transformational experiences.  

On behalf of:  

WELLBEING DIGITAL SCIENCES INC. 

“Adam Deffett”  

Adam Deffett, Interim CEO  

For further information, please contact: 

Nick Kuzyk, Investor Relations  

Tel: 1-844-746-6351  

Email: ir@wellbeingdigital.co  

Web: www.wellbeingdigital.co 

Twitter: @Wellbeing_IR  

Notice Regarding Forward-Looking Information: 

This news release contains forward-looking statements including but not limited to statements regarding  the Company’s business, assets or investments, as well other statements that are not historical facts. Readers  are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that  the plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking  statements involve numerous assumptions, known and unknown risks and uncertainties, both general and  specific, that contribute to the possibility that the predictions, forecasts, projections and other forward 

looking statements will not occur, which may cause actual performance and results in future periods to  differ materially from any estimates or projections of future performance or results expressed or implied by  such forward-looking statements. These assumptions, risks and uncertainties include, among other things,  the state of the economy in general and capital markets in particular, investor interest in the business and  prospects of the Company.  

The forward-looking statements contained in this news release are made as of the date of this news release.  Except as required by law, the Company disclaims any intention and assumes no obligation to update or  revise any forward-looking statements, whether as a result of new information, future events or otherwise,  except as required by applicable securities law. Additionally, the Company undertakes no obligation to  comment on the expectations of, or statements made, by third parties in respect of the matters discussed  above.  

Posted on

Wellbeing Digital Sciences Announces Restructuring of Security-Based Compensation

Wellbeing Digital Sciences Announces Restructuring of Security-Based Compensation

Vancouver, British Columbia, March 28, 2022 / Globe Newswire / – Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based healthcare company focused on innovative clinical solutions, artificial intelligence-powered digital therapeutics and contract research, today announced that it has granted 5,099,999 compensation stock options (the “Options”) and 3,000,000 restricted share units (the “RSUs”) to certain directors, officers, employees, advisors, and consultants of the Company. The Options shall vest immediately and be exercisable into common shares at a price of $0.215 per Option for a period of 5 years from issuance. The RSUs are subject to future vesting with one quarter vesting at each of 3, 6, 9, and 12 months from the date of issuance and shall be exercisable for 24 months. The Options and RSUs are issued as part of its compensation programs to incentivize and retain its board of directors, executives, and managers.

Additionally, the Company announced that it has cancelled 2,975,000 incentive stock options (the “Cancelled Options”) and 5,000,000 RSUs pursuant to the terms of its stock option plan and restricted share unit plan, respectively. The Cancelled Options had been granted between March 22, 2021 and July 5, 2021 to several consultants of the Company and were voluntarily surrendered by the holders for no consideration.

ABOUT WELLBEING DIGITAL SCIENCES

Wellbeing Digital Sciences Inc. is an evidence-based healthcare company focused on innovative clinical solutions, artificial intelligence-powered digital therapeutics and contract research. Its mission is supported by a network of North American clinics that provide ketamine-assisted therapies and other types of treatment to patients as well as through a contract research organization that offers clinical trials services to clients pursuing drug development. In essence, the company exists to make breakthrough treatments more accessible and to offer patients transformational experiences.

On behalf of:

WELLBEING DIGITAL SCIENCES INC.

“Adam Deffett”

Adam Deffett, Interim CEO

For further information, please contact:

Nick Kuzyk, Investor Relations

Tel: 1-844-746-6351

Email: ir@wellbeingdigital.co

Web: www.wellbeingdigital.co

Twitter: @Wellbeing_IR

Notice Regarding Forward-Looking Information:

This news release contains forward-looking statements including but not limited to statements regarding the Company’s business, assets or investments, as well other statements that are not historical facts. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and other forward

looking statements will not occur, which may cause actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. These assumptions, risks and uncertainties include, among other things, the state of the economy in general and capital markets in particular, investor interest in the business and prospects of the Company.

The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities law. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made, by third parties in respect of the matters discussed above.

Posted on

Wellbeing Digital Sciences’ Subsidiary KGK Science Engaged by Lophos Pharmaceuticals for Novel Peyote Study

Wellbeing Digital Sciences’ Subsidiary KGK Science Engaged by Lophos Pharmaceuticals for Novel Peyote Study

The Company’s Wholly Owned Contract Research Organization has Been  Engaged by Lophos Pharmaceuticals to Evaluate a Path to Market for  Sustainably Grown, Peyote-Derived Natural Health Products 

Vancouver, British Columbia, March 21, 2022 / Globe Newswire / – Wellbeing Digital Sciences Inc.  (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based  healthcare company focused on innovative clinical solutions, artificial intelligence-powered digital  therapeutics and contract research, is pleased to announce that its wholly owned subsidiary, KGK Science  Inc. (“KGK”) has been engaged by Lophos Pharmaceuticals Inc. (“Lophos”) to evaluate a path to market  for sustainably grown, peyote-derived natural health products (“NHPs”). Lophos is a Canadian psychedelic  research company focused on cultivation and drug development.  

Peyote has legal status in Canada, but mescaline – the drug derived from the plant– remains a Schedule 3  controlled substance. With a focus on NHPs, potential paths to market will be evaluated based on the safety  and sanitary requirements, quality specifications for peyote-derived inputs, and permissible label claims for  packaging and sales.  

Management Commentary  

“Lophos is currently exploring the potential benefits of a peyote-derived natural health product with the  support of KGK Science. There are challenges to growing peyote, and the thirteen-year-long natural  regrowth cycle is a major threat to the endangered plant. At Lophos, we are researching accelerated,  responsible cultivation techniques for reducing the long growth cycle. The goal is to provide our partners  with therapeutic peyote derivatives, grown in a sustainable manner that are beneficial to the plant itself, and  respectful integrations of traditional medicinal plants,” said Claire Stawnyczy, Founder and CEO of  Lophos.  

“We are very excited to engage with Lophos. Peyote and mescaline in general are currently  underrepresented in the psychedelic medicine sector, given their traditional medicinal uses. Lophos  provides a critically important sustainable supply of cacti to the market. We plan to utilize our expertise in  natural health products to aid Lophos in bringing to market, innovative and safe products for the Canadian  consumer,” added Najla Guthrie, President and CEO of KGK.

ABOUT LOPHOS  

Lophos Pharmaceuticals Inc. is a biosciences company that specializes in Peyote research, cultivation,  preservation, and drug development. We develop novel therapies and natural health treatments that aim to  restore and improve the quality of life for patients. Through advanced cultivation and harvesting techniques,  Lophos will provide our partners with medical grade inputs and our patients with access to safe and effective  mescaline-based therapeutics.  

For more information please contact:  

Alex Krause – Cushion Communications Inc.  

alexkrause.pr@gmail.com 

ABOUT KGK SCIENCE 

Founded in 1997, KGK is a leading North American contract research organization based in London,  Ontario that primarily provides high-quality clinical research trials with a focus on the nutraceutical,  cannabis and emerging psychedelic industries. The business has successfully helped hundreds of companies  with custom designed clinical trials and claim substantiation strategies to move products into global  markets. KGK’s other existing service lines include expert regulatory support and compliance solutions,  participant recruitment, research support services and consulting services. On an approximate basis, the  business to date has produced 150 publications, executed over 400 clinical trials across more than 40  indications, amassed 25,000 participants in its database and collected 10 million data points.  

ABOUT WELLBEING DIGITAL SCIENCES 

Wellbeing Digital Sciences Inc. (formerly KetamineOne Capital Limited) is an evidence-based healthcare  company focused on innovative clinical solutions, artificial intelligence-powered digital therapeutics and  contract research. Its mission is supported by a network of North American clinics that provide ketamine assisted therapies and other types of treatment to patients as well as through a contract research organization  that offers clinical trials services to clients pursuing drug development. In essence, the company exists to  make breakthrough treatments more accessible and to offer patients transformational experiences.  

On behalf of:  

WELLBEING DIGITAL SCIENCES INC. 

“Adam Deffett”  

Adam Deffett, Interim CEO  

For further information, please contact:  

Nick Kuzyk, Investor Relations  

Tel: 1-844-746-6351  

Email: ir@wellbeingdigital.co  

Web: www.wellbeingdigital.co 

Twitter: @Wellbeing_IR  

Notice Regarding Forward-Looking Information: 

This news release contains forward-looking statements including but not limited to statements regarding  the Company’s business, assets or investments, as well other statements that are not historical facts. Readers 

are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that  the plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking  statements involve numerous assumptions, known and unknown risks and uncertainties, both general and  specific, that contribute to the possibility that the predictions, forecasts, projections and other forward 

looking statements will not occur, which may cause actual performance and results in future periods to  differ materially from any estimates or projections of future performance or results expressed or implied by  such forward-looking statements. These assumptions, risks and uncertainties include, among other things,  the state of the economy in general and capital markets in particular, investor interest in the business and  prospects of the Company.  

The forward-looking statements contained in this news release are made as of the date of this news release.  Except as required by law, the Company disclaims any intention and assumes no obligation to update or  revise any forward-looking statements, whether as a result of new information, future events or otherwise,  except as required by applicable securities law. Additionally, the Company undertakes no obligation to  comment on the expectations of, or statements made, by third parties in respect of the matters discussed  above.  

Posted on

Wellbeing Digital Sciences Reports Financial Results for the Second Fiscal Quarter of 2022

Wellbeing Digital Sciences Reports Financial Results for the Second Fiscal Quarter of 2022

Revenue Exceeded $1.6 Million for the Period Ended January 31, 2022

VANCOUVER, British Columbia, March 18, 2022 (GLOBE NEWSWIRE) — Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based healthcare company focused on innovative clinical solutions, artificial intelligence-powered digital therapeutics and contract research, is pleased to announce that it has filed its financial results for the quarter ended January 31, 2022, which is the second quarter of the Company’s 2022 fiscal year ending July 31, 2022, the highlights of which are included in this news release. The full set of Consolidated Financial Statements and Management Discussion and Analysis can be viewed by visiting the Company’s website at www.wellbeingdigital.co or its profile page on SEDAR at www.sedar.com.

Financial Highlights (all amounts expressed in Canadian Dollars unless otherwise noted)

  • Revenue for the quarter ended January 31, 2022 reached $1,660,158, as compared to $nil for the same period of the prior year, which was primarily due to transitioning from an investment issuer to a single-purpose company focused on consolidating medical clinics and becoming a North American leader in mental health treatments;
  • Gross loss for the quarter ended January 31, 2022 was $42,483, as compared to $nil for the same period of the prior year, due to cost of goods sold slightly exceeding revenue for the three-month period;
  • Net loss for the quarter ended January 31, 2022 was $6,503,311, as compared to net loss of $997,171 reported for the same period of the prior year, primarily due to share based payments of $4,029,7765, professional fees of $645,473 and marketing expense of $549,010; and
  • Total assets for the quarter ended January 31, 2022 decreased by 17% to $18,295,698 from $21,921,195 for the period ended July 31, 2021, which was mainly attributable to a decreased in cash and cash equivalents.

Management Commentary

“The second quarter of fiscal 2022 marked our first financial period as Wellbeing Digital Sciences, which began an exciting new chapter for the Company. During the period, KGK Science and IRP Health contributed appropriately and Wellbeing’s prospects for growth are encouraging,” said Adam Deffett, Interim CEO of Ketamine One. “As previously announced, our very own Najla Guthrie will become Chief Executive Officer of the Company effective March 31, 2022. I am grateful to have had the opportunity to lead an organization as dynamic and promising as Wellbeing on an interim basis over most of the last year and am confident that Najla will continue to steward it in a strong direction,” added Mr. Deffett.

‍Subsequent Highlighted Events (all amounts expressed in Canadian Dollars unless otherwise noted)

  • Recent Achievements by KGK Science: On February 2, provided a corporate update highlighting the various achievements of its wholly owned subsidiary, KGK Science Inc., (“KGK” or the “CRO”). Recapping some of 2021’s highlights, KGK won contracts for 11 clinical trial service projects and 5 medical writing projects. Despite the restrictions associated with the COVID-19 pandemic, KGK was able to complete the conduct of 9 clinical trials and advanced several others towards completion. KGK’s Regulatory Division completed 19 consulting projects for clients in the nutraceutical, cannabis and psychedelic spheres. KGK received approvals for eight Product License Applications for Natural Health Products, acknowledgement letters for four unique New Dietary Ingredient Notifications and expert panel consensus that three food ingredients possess Generally Recognized As Safe status.
  • Delivered its First IV Ketamine Treatment Under the Inpatient KITE Program: On February 15, announced the successful facilitation of its first intravenous (“IV”) ketamine treatment to a patient at the Victoria Wellness Mental Health Residential and Addition Treatment Centre (“VW”) in Ontario through its collaboration with iHealthOX. VW is one of the first in-patient facilities to offer ketamine-assisted therapy in Canada. Wellbeing management expects the collaboration between VW, iHealthOX and itself to experience an increase in the number of patients treated via IV ketamine infusions in the near future.
  • IRP Health Received Approval from Veterans Affairs Canada for Reactivation Program: On March 3, announced that its wholly owned subsidiary, IRP Health Ltd. (“IRP”) had recently had its innovative Reactivation therapy program (“Reactivation” or the “Therapy Program”) formally approved by Veterans Affairs Canada (“VAC”) as an interdisciplinary clinic outpatient program at three locations. IRP currently has four clinic locations across Canada and is among the first operators to meet VAC’s new criteria that is aimed at providing high-quality programs for veterans. The Company expects IRP’s location in Ottawa, Ontario to also be approved to offer the Therapy Program by VAC imminently.
  • Appointed Najla Guthrie as Chief Executive Officer: On March 7, announced that Najla Guthrie, the current Chief Research Officer and President of KGK Science Inc. (“KGK”), had been appointed as Chief Executive Officer (“CEO”) of Wellbeing effective March 31, 2022. Adam Deffett who was appointed Interim CEO in July of 2021, will transition out of the role but will continuing in his former capacity as Vice President of Capital Markets and Communications of the Company.

Outlook (excerpt from the Company’s Management Discussion & Analysis for the Period Ended January 31, 2022 and 2021)

The Company is dedicated to becoming a leader in clinical offerings of ketamine-enhanced treatments across North America. We have acquired 15 clinics across North America, with letters of intent signed for an additional clinic. We are building the critical infrastructure needed to provide breakthrough and life-changing mental wellness treatments through existing clinics, experienced professionals and advanced technology.

The Company will be utilizing first-of-its-kind wearable technologies to track key vitals before, during, and after psychedelic-assisted therapies. Our technology aims to empower patients in their wellness journey and provide clinicians with data to improve outcomes. Building objective data around the patient experience by measuring physical signals and responses will allow us to refine and adjust our processes, while providing great opportunities to advance psychedelic therapy research.

KGK Science, a wholly owned subsidiary of the Company, has helped hundreds of companies with custom designed clinical trials and claim substantiation strategies over the past 23 years. Equipped with state-of-the-art technologies, novel research techniques, and a seasoned team of industry experts, KGK Science is a leader in premium clinical research. It has extensive experience in pharmaceuticals, cannabis, natural health products, and more recently psychedelics.

ABOUT WELLBEING DIGITAL SCIENCES

Wellbeing Digital Sciences Inc. (formerly KetamineOne Capital Limited) is an evidence-based healthcare company focused on innovative clinical solutions, artificial intelligence-powered digital therapeutics and contract research. Its mission is supported by a network of North American clinics that provide ketamine-assisted therapies and other types of treatment to patients as well as through a contract research organization that offers clinical trials services to clients pursuing drug development. In essence, the company exists to make breakthrough treatments more accessible and to offer patients transformational experiences.

On behalf of:

WELLBEING DIGITAL SCIENCES INC.

“Adam Deffett“
Adam Deffett, Interim CEO

For further information, please contact:

Nick Kuzyk, Investor Relations
Tel: 1-844-746-6351
Email: ir@wellbeingdigital.co

Web: www.wellbeingdigital.co
Twitter: @Wellbeing_IR

Notice Regarding Forward-Looking Information:

This news release contains forward-looking statements including but not limited to statements regarding the Company’s business, assets or investments, as well other statements that are not historical facts. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. These assumptions, risks and uncertainties include, among other things, the state of the economy in general and capital markets in particular, investor interest in the business and prospects of the Company.

The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities law. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made, by third parties in respect of the matters discussed above.

Posted on

Wellbeing Digital Sciences Appoints Najla Guthrie as Chief Executive Officer

Wellbeing Digital Sciences Appoints Najla Guthrie as Chief Executive Officer

The Company’s Chief Research Officer and President of its Wholly Owned Subsidiary, KGK Science, Will Take Over for Adam Deffett who has Served as Interim CEO Since July 2021


VANCOUVER, British Columbia, March 07, 2022 (GLOBE NEWSWIRE) — Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based healthcare company focused on innovative clinical solutions, artificial intelligence-powered digital therapeutics and contract research, is pleased to announce that Najla Guthrie, the current Chief Research Officer and President of KGK Science Inc. (“KGK”), has been appointed as Chief Executive Officer (“CEO”) of Wellbeing effective March 31, 2022. Adam Deffett who was appointed Interim CEO in July of 2021, will transition out of the role but will continuing in his former capacity as Vice President of Capital Markets and Communications of the Company.

Ms. Guthrie has led KGK, a London, Ontario-based business, to become a leading North American contract research organization that primarily provides high-quality clinical research trials with a focus on the nutraceutical, cannabis, and emerging psychedelic industries. Najla has published over 50 articles in peer-reviewed journals and has given numerous presentations at both the national and international levels. The Company’s management is grateful to have Ms. Guthrie join the leadership team and is excited to see how her contribution will create opportunities for the future.

“I am looking forward to leading the Company through its next stages of growth and development. Adam has exhibited great leadership during his tenure as Interim CEO and I am honored to take over the role at the end of the month. I would like to thank Adam in advance for a smooth transition at that time,” said Najla Guthrie, incoming CEO of Wellbeing. “I greatly appreciate the opportunity to lead Wellbeing as we continue to pursue our vision of becoming a leader in mental health and wellness across North America. We have a leadership team with great depth, decades of experience and detailed knowledge of the industry. Naturally, I will continue to steward KGK Science forward as a leading clinical research organization,” added Ms. Guthrie.

ABOUT WELLBEING DIGITAL SCIENCES

Wellbeing Digital Sciences Inc. (formerly KetamineOne Capital Limited) is an evidence-based healthcare company focused on innovative clinical solutions, artificial intelligence-powered digital therapeutics and contract research. Its mission is supported by a network of North American clinics that provide ketamine-assisted therapies and other types of treatment to patients as well as through a contract research organization that offers clinical trials services to clients pursuing drug development. In essence, the company exists to make breakthrough treatments more accessible and to offer patients transformational experiences.

On behalf of:

WELLBEING DIGITAL SCIENCES INC.

“Adam Deffett“
Adam Deffett, Interim CEO

For further information, please contact:

Nick Kuzyk, Investor Relations
Tel: 1-844-746-6351
Email: ir@wellbeingdigital.co

Web: www.wellbeingdigital.co
Twitter: @Wellbeing_IR

Notice Regarding Forward-Looking Information:

This news release contains forward-looking statements including but not limited to statements regarding the Company’s business, assets or investments, as well other statements that are not historical facts. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. These assumptions, risks and uncertainties include, among other things, the state of the economy in general and capital markets in particular, investor interest in the business and prospects of the Company.

The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities law. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made, by third parties in respect of the matters discussed above.

Posted on

Wellbeing Digital Sciences Subsidiary IRP Health Receives Approval From Veterans Affairs Canada for Reactivation Program

Wellbeing Digital Sciences Subsidiary IRP Health Receives Approval From Veterans Affairs Canada for Reactivation Program

The Company’s Receipt of Approval for the Multidisciplinary “Reactivation” Program Designed by its Wholly Owned Subsidiary is a Major Milestone That is Expected to Benefit Veterans and First Responders for the Foreseeable Future

VANCOUVER, British Columbia, March 03, 2022 (GLOBE NEWSWIRE) — Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: MY0), an evidence-based healthcare company focused on innovative clinical solutions, artificial intelligence-powered digital therapeutics and contract research, is pleased to announce that its wholly owned subsidiary, IRP Health Ltd. (“IRP” or the “Subsidiary”) has recently had its innovative Reactivation therapy program (“Reactivation” or the “Therapy
Program”) formally approved by Veterans Affairs Canada (“VAC”) as an interdisciplinary clinic outpatient program at three locations. IRP currently has four clinic locations across Canada and is among the first operators to meet VAC’s new criteria that is aimed at providing high-quality programs for veterans. The Company expects IRP’s location in Ottawa, Ontario to also be approved to offer the Therapy Program by VAC imminently.

Reactivation is a 12-week, physician-supervised, interdisciplinary pain management program that assists veterans with chronic musculoskeletal injuries and pain. The Therapy Program aims to help veterans return to behaviours that are consistent with being well, rather than behaviours that are consistent with suffering. The goals of Reactivation are to decrease distressing symptoms, increase engagement in the community and increase the ability to complete daily tasks. The Therapy Program also strives to reduce patient disability in both the short and long term, while giving veterans better control and understanding of their pain and health challenges. Reactivation combines psychiatry, psychology, occupational therapy, physiotherapy, kinesiology and dietetics to provide an interdisciplinary approach and a cutting-edge treatment.

Founded in 2016, IRP began as a rehabilitation and performance centre offering exercise therapy and rehabilitation programs in Victoria, British Columbia. IRP builds safe and supportive environments while demonstrating modern, evidence-based physical rehabilitation programs designed specifically for the needs of veterans and first responders. Building on the success of over 15,000 treatments in the flagship Victoria location. IRP is adding new locations and programs to improve access to much needed treatments.

VAC is a government organization for current and former members of the Canadian Armed Forces, Royal Canadian Mounted Police or their family members. It provides services and benefits intended to improve the well-being of veterans and their kin with the estimated total number of veterans in Canada being 617, 800.1 Of these veterans, it is estimated that more than 24% of them have a mental illness, such as PTSD, and 95% of those veterans have been diagnosed with a chronic physical health condition.2 The approval of the Therapy Program has the potential to make a difference in the lives of many veterans who are coping with mental and physical illnesses.

“VAC’s approval of the Reactivation program is a significant milestone for Wellbeing and for the physical and mental health of veterans. This brings us one step closer to achieving our goal of a Canadian wide network of purpose-built programs for veterans and first responders who desperately need access to care,” said Adam Deffett, Interim CEO of Wellbeing. “I am very proud of IRP’s achievements and we fully committed to further expanding their work. These are the moments that fuel Wellbeing’s growth and the achievement of its goals to positively impact the mental health realm,” added Mr. Deffett.

Veterans and first responders looking for more information on Reactivation and IRP locations can visit www.irphealth.ca or call +1 (778) 535-5312.

‍

ABOUT WELLBEING DIGITAL SCIENCES

Wellbeing Digital Sciences Inc. (formerly KetamineOne Capital Limited) is an evidence-based healthcare company focused on innovative clinical solutions, artificial intelligence-powered digital therapeutics and contract research. Its mission is supported by a network of North American clinics that provide ketamine-assisted therapies and other types of treatment to patients as well as through a contract research organization that offer clinical trials services to clients pursuing drug development. In essence, the company exists to make breakthrough treatments more accessible and to offer patients transformational experiences.

On behalf of:

WELLBEING DIGITAL SCIENCES INC.

“Adam Deffett“
Adam Deffett, Interim CEO

For further information, please contact:

Nick Kuzyk, Investor Relations
Tel: 1-844-746-6351
Email: ir@wellbeingdigital.co

Web: www.wellbeingdigital.co
Twitter: @Wellbeing_IR

Notice Regarding Forward-Looking Information:

This news release contains forward-looking statements including but not limited to statements regarding the Company’s business, assets or investments, as well other statements that are not historical facts. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. These assumptions, risks and uncertainties include, among other things, the state of the economy in general and capital markets in particular, investor interest in the business and prospects of the Company.

The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities law. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made, by third parties in respect of the matters discussed above.

Endnotes:

  1. “Demographics”, Government of Canada, March 31 2021, https://www.veterans.gc.ca/eng/about-vac/news-media/facts-figures/1-0
  2. “Understanding mental health”, Government of Canada, March 31 2021, https://www.veterans.gc.ca/eng/health-support/mental-health-and-wellness/understanding-mental-health
Posted on

Wellbeing Digital Sciences Delivers its First IV Ketamine Treatment Under the Inpatient KITE Program

Wellbeing Digital Sciences Delivers its First IV Ketamine Treatment Under the Inpatient KITE Program

The Treatment was Successfully Performed in Ontario as Part of the Company’s  Previously Announced Collaboration with Victoria Wellness and iHealthOX  

Vancouver, British Columbia, February 15, 2022 / Globe Newswire / – Wellbeing Digital Sciences  Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (Frankfurt: MY0), an evidence based healthcare company focused on innovative clinical solutions, artificial intelligence-powered digital  therapeutics and contract research, is pleased to announce the successful facilitation of its first intravenous  (“IV”) ketamine treatment to a patient at the Victoria Wellness Mental Health Residential and Addition  Treatment Centre (“VW” or the “Centre”) in Ontario through its collaboration with iHealthOX. VW is one  of the first in-patient facilities to offer ketamine-assisted therapy in Canada. Wellbeing management expects  the collaboration between VW, iHealthOX and itself to experience an increase in the number of patients  treated via IV ketamine infusions in the near future.  

The Centre, located at 5316 Rice Lake Scenic Drive in Gores Landing, Ontario, is a residential rehabilitation  facility and mental health clinic focused on treating anxiety, depression, and post-traumatic stress disorder  (“PTSD”) by offering personalized therapy treatment programs. The Company and VW have launched a  first-class, best practice-based, six-week inpatient Ketamine Integrated Therapy Experience (“KITE”)  program. The first three weeks of the KITE program are structured to offer clients a unique opportunity to  benefit from fast-acting and medically supervised IV ketamine administration. This process is expected to  help combat long-standing and prescription-resistant mental health conditions such as depression and  PTSD.  

The Company’s previous announced arrangement with iHealthOX helped to make this first IV ketamine  treatment possible. iHealthOX was created to provide patients with a customized digital tool specifically  for mental health. Patients have access to live coaching sessions, options for one-on-one therapy, evidence based educational material, and 24/7 emergency support. The iHealthOX platform will be available to  patients in both desktop and mobile versions, thereby extending the Company’s services beyond its clinic  locations.  

“The success of our first IV ketamine treatment in Canada in collaboration with VW and iHealthOX and  Wellbeing is encouraged that ketamine-based treatments for mental health are becoming more  commonplace. The Company has always wanted to make a positive and significant impact on mental health  and this brings us one step closer,” said Adam Deffett, Interim CEO of Wellbeing. “Achievements like this, 

exemplify why Wellbeing continues to work hard to make a difference in the mental health realm,” added  Mr. Deffett.  

ABOUT WELLBEING DIGITAL SCIENCES 

Wellbeing Digital Sciences Inc. (formerly KetamineOne Capital Limited) is an evidence-based healthcare  company focused on innovative clinical solutions, artificial intelligence-powered digital therapeutics and  contract research. Its mission is supported by a network of North American clinics that provide ketamine assisted therapies and other types of treatment to patients as well as through a contract research organization  that offer clinical trials services to clients pursuing drug development. In essence, the company exists to  make breakthrough treatments more accessible and to offer patients transformational experiences.  

On behalf of:  

WELLBEING DIGITAL SCIENCES INC. 

“Adam Deffett”  

Adam Deffett, Interim CEO  

For further information, please contact:  

Nick Kuzyk, Investor Relations  

Tel: 1-844-746-6351  

Email: ir@wellbeingdigital.co 

Web: www.wellbeingdigital.co 

Twitter: @Wellbeing_IR  

Notice Regarding Forward-Looking Information: 

This news release contains forward-looking statements including but not limited to statements regarding the Company’s business, assets or investments, as well other statements that are not historical facts. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and other forward 

looking statements will not occur, which may cause actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. These assumptions, risks and uncertainties include, among other things, the state of the economy in general and capital markets in particular, investor interest in the business and prospects of the Company.  

The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities law. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made, by third parties in respect of the matters discussed above.